Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27326 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Rebecca Silbermann und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Bortezomib, Dexamethasone. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Alliance Foundation Trials, Janssen Oncology.
Abstract (Originalsprache)
In the phase 2 GRIFFIN trial ( ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D‐RVd) improved depth of response and progression‐free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone (RVd) alone in transplant‐eligible (TE) patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient‐reported outcomes (PROs) collected using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30‐item (QLQ‐C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module 20‐item (QLQ‐MY20), and EuroQol 5‐Dimension 5‐Level (EQ‐5D‐5L) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy. Meaningful improvements from baseline were seen in most of the PRO scales with both treatments after consolidation and were sustained for at least 2 years of maintenance treatment. Large reductions from baseline (~20 points) were especially observed in pain symptoms for both treatment groups, although these were numerically higher for patients receiving D‐RVd during the majority of the time points. In addition, improvements in key scales, such as global health status, fatigue symptoms, and physical functioning, were also seen with both D‐RVd and RVd. These improvements in health‐related quality of life contribute to the totality of evidence supporting the improvement in clinical outcomes such as response rates and PFS with D‐RVd in induction, consolidation, and maintenance therapy in TE patients with NDMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.
- Department of Mematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA.
ORCID-Profile: Jonathan L Kaufman, Brandi Reeves, Luciano J Costa, Katharine S Gries, Peter M Voorhees, Paul G Richardson
Förderung
- NCI NIH HHS
- Alliance Foundation Trials
- Janssen Oncology
Zitieren
APA
Silbermann, R., Laubach, J., Kaufman, J. L., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Costa, L. J., Anderson, L. D., Nathwani, N., Shah, N., Bumma, N., Holstein, S. A., Costello, C., Jakubowiak, A., Orlowski, R. Z., Shain, K. H., Cowan, A. J., Gries, K. S., …, & Richardson, P. G. (2024). Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN. American Journal of Hematology. https://doi.org/10.1002/ajh.27326
Vancouver
Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, et al. Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN. American Journal of Hematology. 2024. doi:10.1002/ajh.27326
BibTeX
@article{Silbermann2024,
author = {Silbermann, Rebecca and Laubach, Jacob and Kaufman, Jonathan L and Sborov, Douglas W and Reeves, Brandi and Rodriguez, Cesar and Chari, Ajai and Costa, Luciano J and Anderson, Larry D and Nathwani, Nitya and Shah, Nina and Bumma, Naresh and Holstein, Sarah A and Costello, Caitlin and Jakubowiak, Andrzej and Orlowski, Robert Z and Shain, Kenneth H and Cowan, Andrew J and Gries, Katharine S and Pei, Huiling and Cortoos, Annelore and Patel, Sharmila and Lin, Thomas S and Voorhees, Peter M and Usmani, Saad Z and Richardson, Paul G},
title = {Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27326}
}
EUVIMED